Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Renna, Nicolas F ^a,b   Diez, Emiliano A ^b   Miatello, Roberto M ^a,b  

^a UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; OXIDOREDUCTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FRUCTOSE; NOS3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; INTRAESOPHAGEAL DRUG ADMINISTRATION; MALE; MESENTERIC ARTERY; METABOLIC SYNDROME X; MICROENVIRONMENT; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; VASCULITIS; ANIMAL; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; GENETICS; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; VASCULAR DISEASES; VASCULAR REMODELING;

ANIMALS; BLOOD PRESSURE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FRUCTOSE; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR DISEASES; VASCULAR REMODELING;

EID: 84906971479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106563     Document Type: Article

References (30)

1. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet; 368:1696-705.
2. Vilsbøll T, Knop F, Krarup T, Johansen A, Madsbad S, et al. (2003) The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide-Regardless of Etiology and Phenotype. Journal of Clinical Endocrinology & Metabolism; 88:4897-903.
3. Timper K, Grisouard J, Sauter NS, Herzog-Radimersk T, Dembinski K, et al. (2013) Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab. 1; 304 (1).
4. Renna NF, Lembo C, Diez E, Miatello R (2013) Role of renin-angiotensin system and oxidative stress on vascular inflammation in insulin resistence model. Int J Hypertens. 2013:420979.
5. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, et al. (2006) TNF-α downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. Oct; 116(10):2791-8.
6. Vomhof-De Krey EE, Picklo MJ (2012) NAD (P) H:quinone oxidoreductase 1 activity reduces hypertrophy in 3T3-L1 adipocytes. Free Radic Biol Med. Aug. 15;53(4):690-700.
7. Barnett A (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. Nov; 60(11):1454-70.
8. Panchapakesan U, Mather A, Pollock C (2013) Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond). Jan 1;124(1):17-26.
9. Carretero O, Oparil S (2000) Essential Hypertension: Part I: Definition and Etiology. Circulation 101(3):329-335.
10. Renna N, Lembo C, Diez E, Miatello R (2012) Vascular repair by endothelial progenitor cells ina an experimental model of metabolic syndrome. In: Lopez Garcia CM, Perez Gonzales PA, editors. Handbook on Metabolic Syndrome: Classification, Risk Factors and Health Impact. Hauppauge, NY: Nova Science Publishers.
11. Keaney JF, Gaziano JM, Xu B, Frei B, Curran-Celentano J, et al. (1993) Dietary Antioxidants Preserve Endothelium-Dependent Vessel Relaxation in Cholesterol-Fed Rabbits. Proc Natl Acad Sci U S A 90(24):11880-11884.
12. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373-376.
13. Ignarro, L Byrns R, Buga G, Wood K (1987) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 61(6):866-879.
14. Renna N, Vazquez MA, Lama MC, González ES, Miatello RM (2009) Effect of chronic aspirin administration on an experimental model of metabolic syndrome. Clin Exp Pharmacol Physiol 36(2):162-8.
15. Fleming I, Busse R (1999) Signal transduction of eNOS activation. Cardiovascular Research. 43(3):532-541.
16. Michel JB, Feron O, Sase K, Prabhakar P, Michel T (1997) Caveolin versus Calmodulin. Journal of Biological Chemistry 272(41):25907-12.
17. Peairs AD, Rankin JW, Lee YW (2011) Effects of acute ingestion of different fats on oxidative stress and inflammation in overweight and obese adults. Nutr J. Nov. 7;10:122.
18. Dong A, Shen J, Zeng M, Campochiaro PA (2011) Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress. Proc Natl Acad Sci U S A 108(35):14614-9.
19. Renna NF, de Las Heras N, Miatello RM (2013) Pathophysiology of vascular remodeling in hypertension. Int J Hypertens. 2013:808353.
20. Siegel D, Swislocki A (2007) Effects of antihypertensives on glucose metabolism. Metab. Syndr. Relat. Disord. 5:211-219.
21. Renna NF, Diez ER, Lembo C, Miatello RM (2013) Role of Cox-2 in vascular inflammation: an experimental model of metabolic syndrome. Mediators Inflamm. 2013:513251.
22. Renna NF, Vazquez MA, Lama MC, González ES, Miatello RM (2009) Effect of chronic aspirin administration on an experimental model of metabolic syndrome. Clin Exp Pharmacol Physiol 36(2):162-8.
23. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, et al. (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084.
24. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965.
25. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, et al. (2007) Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293:E1289-E1295.
26. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209-E1215.
27. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, et al. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and - independent pathways. Circulation 117:2340-2350.
28. Muniyappa R, Montagnani M, Koh KK, Quon MJ (2007) Cardiovascular actions of insulin. Endocr Rev 28:463-491.
29. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, et al. (2011) Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis. Circulation. 124:2338-2349.
30. Ussher JR, Drucker DJ (2012) Cardiovascular Biology of the Incretin System. Endocrine Reviews 33:187-215.